- Home
- OLMA
as 12-18-2024 10:41am EST
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | 2006 | Country: | United States |
| Employees: | 88 | City: | SAN FRANCISCO |
| Market Cap: | 465.4M | IPO Year: | 2020 |
| Target Price: | $26.25 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.10 - $16.78 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Olema Pharmaceuticals Inc. (OLMA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zojwalla Naseem | OLMA | CHIEF MEDICAL OFFICER | Dec 9 '24 | Sell | $9.14 | 27,805 | $250,455.83 | 130,031 | |
| Bohen Sean | OLMA | PRESIDENT AND CEO | Dec 9 '24 | Sell | $9.14 | 109,502 | $986,365.11 | 298,836 |
Latest Olema Pharmaceuticals Inc. News
OLMA Breaking Stock News: Dive into OLMA Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
MT Newswires
9 days ago
Olema Pharmaceuticals Cleared to Begin Testing Prospective Breast Cancer Candidate
GlobeNewswire
9 days ago
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
GlobeNewswire
15 days ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
15 days ago
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
Pharmaceutical Technology
15 days ago
Novartis and Olema expand alliance with $250m to boost breast cancer trials
MT Newswires
16 days ago
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement
GlobeNewswire
16 days ago
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
Compare OLMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OLMA Olema Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.